As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...
Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
Louisiana woman Jaclyn Bjorklund (44) took Novo Nordisk's GLP-1 ... drugs for diabetes and follow-up indications such as obesity. Novo Nordisk already has approval for semaglutide under the Wegovy ...